Accueil   Diary - News   All news ElsaLys Biotech acquires rights of Transgene’s anti-CD115 antibody

ElsaLys Biotech acquires rights of Transgene’s anti-CD115 antibody

Elsalys logo_vertical_CMJN

 

 

  • Initially developed by Transgene, one of ElsaLys Biotech’s founding shareholders, this antibody inhibits a deleterious subpopulation of macrophages found in the tumor microenvironment.
  • Based on the initial preclinical data, ElsaLys Biotech will give priority to developing ELB 041 (anti-CD115) in immuno-oncology, the goal being to launch a first clinical trial in 24 months.
  • ElsaLys Biotech is now conducting five antibody programs in oncology and ophthalmology.

 

Read the press release

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree